Literature DB >> 14556645

Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients.

Luis A Videla1, Ramón Rodrigo, Myriam Orellana, Virginia Fernandez, Gladys Tapia, Luis Quiñones, Nelson Varela, Jorge Contreras, Raúl Lazarte, Attila Csendes, Jorge Rojas, Fernando Maluenda, Patricio Burdiles, Juan C Diaz, Gladys Smok, Lilian Thielemann, Jaime Poniachik.   

Abstract

Oxidative stress is implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). In the present study, hepatic and plasma oxidative stress-related parameters were measured and correlated with clinical and histological findings in 31 NAFLD patients showing increased body mass index. Liver protein carbonyl content was enhanced by 403% in patients with steatosis (n=15) compared with control values (n=12), whereas glutathione content, superoxide dismutase (SOD) activity and the ferric reducing ability of plasma (FRAP) were decreased by 57%, 48% and 21% (P<0.05) respectively. No changes in microsomal p-nitrophenol hydroxylation and the total content of cytochrome P450 (CYP) or CYP2E1 were observed. Patients with steatohepatitis (n=16) exhibited protein carbonyl content comparable with that of controls, whereas glutathione content, SOD and catalase activities were decreased by 27%, 64% and 48% (P<0.05). In addition, FRAP values in patients with steatohepatitis were reduced by 33% and 15% (P<0.05) when compared with controls and patients with steatosis respectively, whereas p-nitrophenol hydroxylation (52%) and CYP2E1 content (142%) were significantly increased (P<0.05) compared with controls. It is concluded that oxidative stress is developed in the liver of NAFLD patients with steatosis and is exacerbated further in patients with steatohepatitis, which is associated with CYP2E1 induction. Substantial protein oxidation is followed by proteolysis of the modified proteins, which may explain the co-existence of a diminished antioxidant capacity and protein oxidation in the liver of patients with steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14556645     DOI: 10.1042/CS20030285

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  139 in total

1.  Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Takhar Kasumov; John M Edmison; Srinivasan Dasarathy; Carole Bennett; Rocio Lopez; Satish C Kalhan
Journal:  Metabolism       Date:  2010-09-23       Impact factor: 8.694

Review 2.  Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances.

Authors:  Mohamed A Abdelmegeed; Seung-Kwon Ha; Youngshim Choi; Mohammed Akbar; Byoung-Joon Song
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

3.  Sonographic fatty liver, overweight and ischemic heart disease.

Authors:  Yu-Cheng Lin; Huey-Ming Lo; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

4.  Abnormal liver function and central obesity associate with work-related fatigue among the Taiwanese workers.

Authors:  Yu-Cheng Lin; Jong-Dar Chen; Chao-Jen Chen
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

Review 5.  Lipotoxicity in the liver.

Authors:  Veronika Zámbó; Laura Simon-Szabó; Péter Szelényi; Eva Kereszturi; Gábor Bánhegyi; Miklós Csala
Journal:  World J Hepatol       Date:  2013-10-27

6.  N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis.

Authors:  January N Baumgardner; Kartik Shankar; Leah Hennings; Emanuele Albano; Thomas M Badger; Martin J J Ronis
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

Review 7.  Nrf2: a potential target for new therapeutics in liver disease.

Authors:  A M Bataille; J E Manautou
Journal:  Clin Pharmacol Ther       Date:  2012-08-08       Impact factor: 6.875

Review 8.  Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Kazuhiro Kotoh; Manabu Nakashima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

10.  In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.

Authors:  Jeffrey B Schwimmer; Joel E Lavine; Laura A Wilson; Brent A Neuschwander-Tetri; Stavra A Xanthakos; Rohit Kohli; Sarah E Barlow; Miriam B Vos; Saul J Karpen; Jean P Molleston; Peter F Whitington; Philip Rosenthal; Ajay K Jain; Karen F Murray; Elizabeth M Brunt; David E Kleiner; Mark L Van Natta; Jeanne M Clark; James Tonascia; Edward Doo
Journal:  Gastroenterology       Date:  2016-08-26       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.